In the last trading session, 1.65 million Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares changed hands as the company’s beta touched 0.92. With the company’s per share price at $19.53 changed hands at $0.67 or 3.55% during last session, the market valuation stood at $2.46B. ARWR’s last price was a discount, traded about -88.02% off its 52-week high of $36.72. The share price had its 52-week low at $17.05, which suggests the last value was 12.7% up since then.
Analysts gave the Arrowhead Pharmaceuticals Inc (ARWR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended ARWR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Arrowhead Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.47.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Instantly ARWR was in green as seen at the end of in last trading. With action -4.45%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 3.88%, with the 5-day performance at -4.45% in the red. However, in the 30-day time frame, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is -5.92% down.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 27.67% from its current market value. According to analyst projections, ARWR’s forecast low is 24 with 29.97 as the target high. To hit the forecast high, the stock’s price needs a -53.46% plunge from its current level, while the stock would need to soar -22.89% for it to hit the projected low.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
Year-over-year growth is forecast to reach 8,104.36% up from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 118.54M. 11 analysts are of the opinion that Arrowhead Pharmaceuticals Inc’s revenue for the current quarter will be 40.81M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Arrowhead Pharmaceuticals Inc earnings to increase by 46.57%, but the outlook for the next 5-year period is at 9.82% per year.
ARWR Dividends
Arrowhead Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.9072% or 12.21 million shares worth $317.44 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Core S&P Midcap ETF and Vanguard Total Stock Market Index Fund . With 3.99 shares estimated at $77.98 million under it, the former controlled 3.17% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.94% of the shares, roughly 3.71 shares worth around $72.39 million.
